RVMD

RVMD

USD

Revolution Medicines Inc. Common Stock

$58.570+0.580 (1.000%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$57.990

High

$59.680

Low

$57.740

Volume

2.37M

Company Fundamentals

Market Cap

10.9B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

2.19M

Exchange

NMS

Currency

USD

52-Week Range

Low $29.17Current $58.570High $62.4

Related News

Analyst Upgrades

RBC Capital Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $77

RBC Capital analyst Leonid Timashev initiates coverage on Revolution Medicines with a Outperform rating and announces Price Target of $77.

View more
RBC Capital Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $77
GlobeNewswire

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today

View more
Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
GlobeNewswire

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today

View more
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor
Analyst Upgrades

Mizuho Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $90

Mizuho analyst Joseph Catanzaro initiates coverage on Revolution Medicines with a Outperform rating and announces Price Target of $90.

View more
Mizuho Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $90